On Wednesday, the 5th U.S. Circuit Court of Appeals held a hearing to review a legal challenge aimed at curtailing access to mifepristone, a medication commonly used for abortion. The three-judge panel questioned legal representatives from the state of Louisiana, the Food and Drug Administration (FDA), and two companies involved in the manufacturing and distribution of the drug.

The core of the legal dispute centers on whether the FDA’s recent regulatory changes—which have made the medication more accessible—were implemented in accordance with federal law. Attorneys for the state of Louisiana argued that the federal government overstepped its authority, while representatives for the FDA and the pharmaceutical companies maintained that the agency’s decisions were based on sound scientific evidence and established regulatory procedures.

The outcome of this case carries significant implications for reproductive healthcare nationwide. If the court rules in favor of the plaintiffs, it could potentially lead to a nationwide reduction in access to medication abortion, including in states where abortion remains legal and protected. Conversely, a ruling upholding the FDA’s current regulations would maintain the status quo. The judges did not issue a ruling on Wednesday, and it remains unclear when a decision will be handed down. The case is expected to face further appeals regardless of the panel's eventual ruling, potentially setting the stage for a future Supreme Court review.